For analysis, we kept only trials that fulfilled four requirements: (a) there were no blinks or signal loss during the trial; (b) fixation was kept on the fixation point (±0.5°); (c) after a saccade, the eye correctly landed on the new fixation location and fixation was kept on the fixation point (±0.5°); and (d) the saccade was performed during two ISIs: either between 90 and 140 ms stimulus onset asynchrony (SOA) or between 160 and 210 ms SOA (in the saccade conditions). The third requirement implies that we kept only trials in which: (1) the saccade was performed between the presentation of the central offset and the presentation of the flanking line offset; (2) no line was presented on the screen during the saccade; and (3) after the saccade, at least one straight line was presented before the flanking line offset. As an example, the saccade dataset of one observer is displayed in
Supplementary Figure S1.
A total of 5099 trials (49.8%) were kept in Experiment 1: in the fixation condition, V (398 trials, 62.2%), AV (390 trials, 60.9%), V-AV (383 trials, 59.8%), and V-PV (358 trials, 55.9%); in the spatiotopic condition, V (283 trials, 44.2%), AV (253 trials, 39.5%), V-AV (211 trials, 33%), and V-PV (231 trials, 36.1%); in the retinotopic condition, V (292 trials, 45.6%), AV (241 trials, 37.7%), V-AV (268 trials, 41.9%), and V-PV (239 trials, 37.3%); and in the jump condition, V (377 trials, 58.9%), AV (389 trials, 60.8%), V-AV (385 trials, 60.2%), and V-PV (401 trials, 62.7%). In the fixation and jump conditions, 18.4% and 81.6% of the excluded trials were due to criteria (a) and (b), respectively. In the saptiotopic and retinotopic conditions, 8.1%, 4.5%, 30.8%, and 56.6% of the excluded trials were due to criteria (a), (b), (c), and (d), respectively.
In Experiment 2, 1962 trials (37.2%) were kept for analysis: in the
fixation condition, V (245 trials, 51%), AV (196 trials, 40.8%), and V-AV (271 trials, 56.5%); in the
spatiotopic condition, V (126 trials, 26.3%), AV (166 trials, 34.6%), V-AV R[V] (132 trials, 27.5%), and V-AV R[AV] (135 trials, 28.1%); and in the
retinotopic condition, V (171 trials, 36.6%), AV (154 trials, 32.1%), V-AV R[V] (185 trials, 38.5%), and V-AV R[AV] (181 trials, 37.7%). In the fixation condition, 7.4% and 92.6% of the excluded trials were due to criteria (a) and (b), respectively. In the saptiotopic and retinotopic conditions, 4.2%, 1.3%, 26%, and 68.5% of the excluded trials were due to criteria (a), (b), (c), and (d), respectively. Analyses were also performed on the raw data and did not change the conclusions (
Supplementary Figures S2 and
S3).